electroCore (NASDAQ:ECOR) Earns “Buy” Rating from HC Wainwright

electroCore (NASDAQ:ECOR)‘s stock had its “buy” rating reaffirmed by stock analysts at HC Wainwright in a research report issued on Thursday,Benzinga reports. They presently have a $25.00 price target on the stock. HC Wainwright’s price target would indicate a potential upside of 192.06% from the company’s current price. HC Wainwright also issued estimates for electroCore’s FY2028 earnings at $2.25 EPS and FY2029 earnings at $3.07 EPS.

electroCore Price Performance

Shares of NASDAQ ECOR opened at $8.56 on Thursday. electroCore has a 1 year low of $5.32 and a 1 year high of $19.49. The company’s 50-day moving average is $15.84 and its 200 day moving average is $12.26. The stock has a market capitalization of $56.98 million, a P/E ratio of -4.68 and a beta of 0.24.

Hedge Funds Weigh In On electroCore

Several hedge funds and other institutional investors have recently modified their holdings of the stock. JPMorgan Chase & Co. increased its position in shares of electroCore by 31,250.0% during the fourth quarter. JPMorgan Chase & Co. now owns 3,762 shares of the company’s stock valued at $61,000 after buying an additional 3,750 shares during the period. Geode Capital Management LLC increased its position in shares of electroCore by 10.3% during the third quarter. Geode Capital Management LLC now owns 63,485 shares of the company’s stock valued at $458,000 after buying an additional 5,951 shares during the period. DnB Asset Management AS purchased a new stake in electroCore in the fourth quarter worth about $180,000. NewEdge Advisors LLC purchased a new stake in electroCore in the fourth quarter worth about $274,000. Finally, Jane Street Group LLC purchased a new stake in electroCore in the fourth quarter worth about $278,000. Hedge funds and other institutional investors own 26.74% of the company’s stock.

electroCore Company Profile

electroCore, Inc, a commercial stage bioelectronic medicine and wellness company, provides non-invasive vagus nerve stimulation technology platform in the United States, the United Kingdom, and internationally. The company is developing gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania.